Reference

Compare peptides

Two to four compounds, field by field: identity, United States regulatory status, and what kinds of documents are on file. The table records differences. It does not rank them.

Compound 1

Compound 2

Compound 3 (optional)

Compound 4 (optional)

No winner, no score, no recommendation. Counts describe how many documents of each kind Therapept has indexed — not how well a compound works, and not how much has been published overall.

Link to this comparison: /compare?peptides=gt20029,retatrutide,cagrilintide

Side-by-side comparison of GT20029, Retatrutide, Cagrilintide
Identity
	GT20029	Retatrutide	Cagrilintide
Class	Investigational topical androgen-receptor degrader (PROTAC), developed by Kintor Pharmaceutical	Investigational triple agonist of GIP, GLP-1 and glucagon receptors	Investigational long-acting acylated amylin analogue
Also listed as	GT-20029, Kintor AR degrader	LY3437943, LY-3437943	Not recorded
Molecular formula	Not recorded	Not recorded	C194H312N54O59S2
Molecular weight	Not recorded	4731.33 g/mol (average mass, widely cited for the free base)	4409 g/mol
CAS	Not recorded	2381089-83-2	1415456-99-3
PubChem CID	Not recorded	Not recorded	171397054
Sequence length	Not recorded	Not recorded	Described structurally, not as a residue list
Data caveat	None recorded	PubChem’s retatrutide record states a CID is not available as a discrete structure. Full caveat	None recorded
United States regulatory status
Status	Investigational	Investigational	Investigational
FDA application	None recorded	None recorded	None recorded
Compounding	No FDA compounding entry recorded	No FDA compounding entry recorded	No FDA compounding entry recorded
WADA	Not named in this record	Not named in this record	Not named in this record
Research profile
Research purpose	Topical androgen-receptor degradation	Triple-agonist metabolic research	No plain-English profile recorded
Proposed mechanism	A topical PROTAC-type molecule intended to mark androgen receptors for degradation, reducing androgen signalling in the follicle. The published Phase 2 trial tests the clinical consequence of that mechanism.	Proposed triple agonism: GLP-1 and GIP effects on appetite and insulin, plus glucagon-receptor signalling in the liver and energy expenditure. The net clinical contribution of each arm is still being studied.	No plain-English profile recorded
Human evidence	A randomised, placebo-controlled Phase 2 trial in 180 Chinese men with androgenetic alopecia was published in 2025. No Phase 3 trial or approval exists.	A published 48-week Phase 2 trial in 338 adults, plus Phase 3 trials registered and sponsor topline disclosures. No approved product exists.	No plain-English profile recorded
Evidence tier	Phase 2 trials registered or reported	Phase 3 trials registered or reported	No plain-English profile recorded
Known safety concerns	Phase 2 adverse events were mostly mild and similar across groups, according to the published report. Long-term effects of sustained androgen-receptor degradation in skin are unknown. No public chemical identity standard was identified, which limits independent quality assessment.	Gastrointestinal adverse effects were reported in the Phase 2 trial. Resting heart rate increased transiently in the Phase 2 trial. The full Phase 3 safety database and any regulatory review are not public as an approved label.	No plain-English profile recorded
Evidence gaps	Phase 3 confirmation in a broader population. Durability after treatment stops. Long-term safety of local androgen-receptor degradation. A public identity standard for the drug substance.	Peer-reviewed Phase 3 results, including full adverse-event tables. Long-term cardiovascular and lean-mass outcomes. Any regulatory decision.	No plain-English profile recorded
Head-to-head evidence	No published head-to-head trial against finasteride, minoxidil or any other hair-loss treatment.	No published head-to-head trial against semaglutide or tirzepatide. Cross-trial comparisons are not head-to-head evidence.	No plain-English profile recorded
Named pathways	Androgen receptor · Ubiquitin-proteasome degradation · DHT signalling	GIP receptor · GLP-1 receptor · Glucagon receptor · Hepatic lipid oxidation · Energy expenditure	No plain-English profile recorded
Evidence on file
Records	1Open evidence file	2Open evidence file	0Open evidence file
Human-interventional records	1	2	0
Human-observational records	0	0	0
Animal records	0	0	0
In-vitro records	0	0	0
Reviews	0	0	0
Regulatory documents	0	0	0
Earliest indexed	2025	2023	Not recorded
Latest indexed	2025	2026	Not recorded

Every identity and regulatory value above is taken from the compound’s record, where its sources are listed. Evidence counts are derived from the published evidence file at build time. A missing class means no document of that kind is indexed — not that none exists.